Leap Therapeutics, Inc.
LPTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.02 | 0.00 | 0.05 |
| FCF Yield | -97.17% | -117.72% | -115.00% | -13.06% |
| EV / EBITDA | 0.18 | 0.35 | 1.29 | -3.56 |
| Quality | ||||
| ROIC | -10.13% | -293.28% | -75.82% | -121.05% |
| Gross Margin | -9,631.58% | 0.00% | 0.00% | -4,461.54% |
| Cash Conversion Ratio | 0.63 | 0.87 | 0.94 | 1.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -36.34% | -59.16% | -65.97% | -70.21% |
| Free Cash Flow Growth | -26.22% | -0.04% | 6.65% | 0.56% |
| Safety | ||||
| Net Debt / EBITDA | 0.93 | 1.09 | 2.11 | 2.33 |
| Interest Coverage | -2,786.10 | -2,411.57 | -2,652.83 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 19.79 | 0.00 | 0.00 | 230.78 |